Among these, nine phase 2 trials have been performed with stratification of p53 status in cancers, including ovarian cancer (NCT01164995, NCT01357161, NCT02272790), relapsed SCLC (NCT02688907, NCT02593019), untreated non-small cell lung cancer (NSCLC, NCT02087241), NSCLC (NCT02087176), recurrent uterine serous carcinoma (NCT03668340), and colorectal carcinoma (FOCUS4-C). Here, TP53 is linked to endometrial serous adenocarcinoma.